Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2021, to shareholders recorded by close of business on November 15, 2021. This move reflects the company's commitment to delivering value to its shareholders. Teleflex is a global provider of medical technologies, focusing on improving health and quality of life through innovative solutions in various medical fields. For more details, visit teleflex.com.
Teleflex reported strong financial results for Q3 2021, with revenues of $700.3 million, reflecting an 11.5% year-over-year increase. GAAP diluted EPS rose to $4.20, up from $2.46 a year prior, while adjusted diluted EPS reached $3.51, a 26.7% increase. Despite these positive results, the company lowered its revenue growth guidance due to COVID-19 impacts, now projecting 10-11% GAAP revenue growth and 8-9% constant currency growth. CEO Liam Kelly noted challenges, particularly for the UroLift product line, but emphasized the benefits of a diversified product portfolio.
Teleflex (NYSE: TFX) has completed patient enrollment in a clinical study assessing the QuikClot Control+® Hemostatic Device for mild to moderate bleeding during cardiac surgeries. The study, which aimed to measure hemostasis rates, enrolled 231 patients across seven sites, finishing three months ahead of schedule. Principal investigators express optimism about sharing findings related to various cardiac procedures. The QuikClot Control+® is FDA-cleared for severe bleeding but is investigational in this study, with plans for a 510(k) filing upon analysis completion.
Teleflex Incorporated (NYSE: TFX) will host a conference call to discuss its third quarter financial results on October 28, 2021, at 8:00 a.m. Eastern Time. Interested parties can register for the call via a provided link, which will also allow access to a live audio webcast on the company's website. An audio replay will be available following the call. Teleflex is a global provider of medical technologies, focusing on innovation to meet clinical needs and improve healthcare outcomes.
Teleflex announced new data at the American Urological Association meeting indicating that the UroLift System has the lowest rate of return procedures among treatments for benign prostatic hyperplasia (BPH). The study compared outcomes of UroLift with TURP, GreenLight, and Rezūm using data from U.S. Medicare and commercial claims from 2015 to 2019, which included over 35,000 patients. The findings highlight that while surgical retreatment rates are similar between UroLift, TURP, and GreenLight, Rezūm showed a significantly higher rate of surgical retreatment, positioning UroLift as a preferred option for BPH treatment.
On September 9, 2021, Teleflex announced the launch of two innovative products for the UroLift System: the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System. These products enhance treatment for benign prostatic hyperplasia (BPH) and will be showcased at the AUA Annual Meeting. The UroLift ATC features an improved delivery device for easier treatment, while the UroLift 2 System offers enhancements for user confidence. Data presented at the meeting will demonstrate the efficacy and safety of UroLift procedures, crucial for BPH management in men 45 and older.
Teleflex Incorporated (NYSE: TFX) will have Chairman, President, and CEO Liam Kelly speaking at the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 8:00 a.m. ET. The event will feature a live audio webcast and a slide presentation available on Teleflex's investor website.
Teleflex is dedicated to improving healthcare through innovative medical technologies across various fields, including vascular access and emergency medicine. For more details, visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) announced the publication of clinical data for the UroLift® System in the peer-reviewed journal Prostate Cancer and Prostatic Disease. The study highlights the system's efficacy in treating benign prostatic hyperplasia (BPH) and revealed long-term stability and low complication rates. Data from over 770,000 UroLift devices showed minimal breakage (0.004%) and encrustation (0.006%). The procedure offers rapid relief without common issues found in previous treatments, benefiting over 250,000 patients globally. The research asserts UroLift's superior durability and patient experience, promising a sustainable solution for BPH.
Teleflex's CEO, Liam Kelly, will address the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 12:40 PM (ET). A live audio webcast along with a slide presentation will be accessible through the Teleflex investor section website. The company specializes in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, interventional cardiology, and emergency medicine. For more information, visit teleflex.com.
Teleflex announced a quarterly cash dividend of $0.34 per share, payable on September 15, 2021, to shareholders of record by August 16, 2021. This decision reflects the company's commitment to returning value to its shareholders through consistent dividend payments. Teleflex, a global leader in medical technologies, emphasizes innovation to meet clinical needs across various healthcare sectors, ensuring improved health outcomes for patients.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
